Recently, we found ERα antagonist (MPP) and ERβ agonist (DPN) significantly suppressed ovarian cancer cell growth in vitro and in vivo, suggesting that targeting ER subtypes may be applicable to ovarian cancer patients [15]. Here, ESR1 is linked to ovarian carcinoma.